Golden
Galera Therapeutics

Galera Therapeutics

A company developing therapeutics for the treatment of cancer

All edits

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:21 pm
Edits made to:
Infobox (+1 properties)
Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 30 Mar 2019
Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 1:59 pm
Edits made to:
Infobox (+1 properties)
Article (+17/-17 characters)

Article

Galera Therapeutics is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapyradiation therapy is used in patients with cancer.

Infobox

Dawson Sewell
Dawson Sewell edited on 30 Mar 2019 1:54 pm
Edits made to:
Infobox (+3/-1 properties)
Categories (+1/-2 topics)
Related Topics (+1 topics)
Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:14 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 9:44 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 3 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 3 Jan 2019 8:36 pm
Edits made to:
Article (+16/-16 characters)

Article

The FDA has granted Breakthrough Therapy designation to GC4419 for the reduction of the duration, incidence, and severity of SOM induced by radiation therapy with or without systemic therapysystemic therapy. It has also granted Fast Track designation to GC4419 for the reduction of the severity and incidence of radiation and chemotherapy-induced OM.

Edits on 24 Dec 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 24 Dec 2018 7:34 pm
Edits made to:
Article (+20/-20 characters)

Article

Galera's lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutasesuperoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. Radiation therapy generates elevated superoxide levels that can damage non-cancerous tissues and lead to debilitating side effects that may limit the anti-tumor efficacy of radiation therapy.

Edits on 23 Dec 2018
Sameeha Sulaiman
Sameeha Sulaiman edited on 23 Dec 2018 3:59 pm
Edits made to:
Infobox (+1/-1 properties)
Article (+1422 characters)
People (+14 cells) (+212 characters)

Article

Galera Therapeutics is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer.



Galera's lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. Radiation therapy generates elevated superoxide levels that can damage non-cancerous tissues and lead to debilitating side effects that may limit the anti-tumor efficacy of radiation therapy.



GC4419 has been studied in patients with head and neck cancer for it's ability to reduce the incidence and duration of radiation-induced severe oral mucositis (SOM). In addition, multiple preclinical studies, GC4419 has demonstrated an increased tumor response to radiation therapy while preventing toxicity in normal tissue. 



The FDA has granted Breakthrough Therapy designation to GC4419 for the reduction of the duration, incidence, and severity of SOM induced by radiation therapy with or without systemic therapy. It has also granted Fast Track designation to GC4419 for the reduction of the severity and incidence of radiation and chemotherapy-induced OM.

...

The rest of Galera's portfolio consist of other dismutase mimetic product candidates, both in clinical and earlier stage.

People

Name
Role
Related Golden topics

Arthur Fratamico

Chief Business Officer



Dennis P. Riley

Chief Scientific Officer



Joel Sussman

CFO



Jon T. Holmlund

Chief Medical Officer



Mel Sorensen

President & CEO



Robert A Beardsley

COO



Stephen Ross

Chief Commercial Officer



Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:09 am
Edits made to:
Infobox (+3 properties)
People (+4 cells) (+43 characters)
Categories (+1 topics)

People

Name
Role
Related Golden topics

Enso Ventures

Investor



Ryan Rakestraw

Investor



Infobox

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:52 pm

Infobox

Location
Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:42 pm
Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:52 pm
Edits made to:
Description (+61/-21 characters)
Topic thumbnail

Galera Therapeutics

Biotechnology company

A company developing therapeutics for the treatment of cancer

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:31 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Galera Therapeutics

Biotechnology company

Categories

No more activity to show.